🔎 Trials Near Me

Akèy › Obèsite › Arizona

Etid klinik pou Obèsite nan Arizona

40 etid pou Obèsite ap chèche patisipan nan sit nan Arizona.

Vil nan Arizona

Tèks ofisyèl etid la (Anglè)

Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

  • Headlands Research - Scottsdale /ID# 282571, Scottsdale
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT07752979

A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event

  • Pima Heart, Tucson
  • Eclipse Clinical Research, Tucson
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07783802

Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss

  • AMR Clinical, Tempe
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 28, 2026 · NCT07837973

Early Tracking of Childhood Health Determinants (ETCHED) Study

  • NIDDK, Phoenix, Phoenix
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
1 Day – 99 Years · Tout sèks · Mizajou Sep 28, 2026 · NCT03481829

A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

  • University of Arizona, Tucson
Ap rekriteFaz 3
Laj 6 a 17 · Tout sèks · Mizajou Sep 24, 2026 · NCT06672549

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

  • Tucson Clinical Research Institute, Tucson
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07282600

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

  • RIO Clinical Trials - Phoenix, Phoenix
  • Headlands Research - Scottsdale, Scottsdale
  • Novak Clinical Research - Tucson - North La Cholla Boulevard, Tucson
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07392190

A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight

  • Research Site, Mesa
  • Research Site, Phoenix
  • Research Site, Tucson
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07784270

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

  • Synexus Clinical Research US, Inc., Phoenix
  • Medical Advancement Centers of Arizona, Phoenix
Ap rekriteFaz 3
Laj 45 a 99 · Tout sèks · Mizajou Sep 22, 2026 · NCT07037433

A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

  • Headlands Research - Scottsdale, Scottsdale
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07321886

Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

  • Care Access - 801 South Power Road, Mesa, Mesa
  • Elite Pain and Spine Institute - South Crimson Road, Mesa
  • Elite Clinical Studies, LLC, Phoenix
  • ak 1 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07353931

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

  • The Institute for Liver Health II dba Arizona Clinical Trials - Mesa, Chandler
  • Headlands Research - Scottsdale, Scottsdale
  • The Institute for Liver Health II dba Arizona Liver Health-Tucson, Tucson
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 22, 2026 · NCT07589608

Variability In Mixed Meal Tests: Fixed Versus Adjusted to Energy Needs Caloric Dose

  • NIDDK, Phoenix, Phoenix
Ap rekriteVolontè an sante akeyi
Laj 18 a 99 · Tout sèks · Mizajou Sep 21, 2026 · NCT06223555

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

  • AURORA-1 Clinical Site, Phoenix
  • AURORA-1 Clinical Site, Tucson
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT07743463

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

  • AURORA-2 Clinical Site, Peoria
  • AURORA-2 Clinical Site, Phoenix
  • AURORA-2 Clinical Site, Tucson
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT07743450

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

  • HonorHealth, Phoenix
  • Medical Advancement Centers of Arizona, Phoenix
  • Pima Heart and Vascular Clinical Research, Tucson
  • ak 1 plis
Ap rekriteFaz 3
Laj 18 a 99 · Tout sèks · Mizajou Sep 16, 2026 · NCT07037459

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

  • Arizona Clinical Trials, Tucson
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT07351058

A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

  • Helios Clinical Research - Phoenix, Phoenix
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 14, 2026 · NCT06897475

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

  • Arizona Clinical Trials, Tucson
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT07351045

A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

  • ACCOMPLISH-2 Research Site, Chandler
  • ACCOMPLISH-2 Research Site, Phoenix
  • ACCOMPLISH-2 Research Site, Sun City West
  • ak 1 plis
Ap rekriteFaz 3Volontè an sante akeyi
Laj 18 a 79 · Tout sèks · Mizajou Sep 11, 2026 · NCT07654374

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

  • The Institute for Liver Health II dba Arizona Clinical Trials - Mesa, Chandler
  • Headlands Research - Scottsdale, Scottsdale
  • The Institute for Liver Health II dba Arizona Liver Health-Tucson, Tucson
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 8, 2026 · NCT06143956

A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

  • Prime Medical Group, LLC dba Gilbert Center for Family Medicine, LLC, Gilbert
  • Synexus Clinical Research US, Inc., Phoenix
  • Pima Heart, Tucson
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 8, 2026 · NCT07215559

Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

  • Kailera Clinical Site, Phoenix
  • Kailera Clinical Site, Sun City
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT07284901

Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

  • Kailera Clinical Site, Sun City
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT07284875

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)

  • Gilbert Center for Family Medicine, Gilbert
Ap rekriteFaz 3
Laj 18 a 99 · Tout sèks · Mizajou Sep 3, 2026 · NCT07684144

Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes

  • Kailera Clinical Site, Glendale
  • Kailera Clinical Site, Phoenix
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 1, 2026 · NCT07284979

The Effects of Increasing Caloric Intake on Diet-Induced Thermogenesis and 24h Energy Expenditure

  • NIDDK, Phoenix, Phoenix
Ap rekriteVolontè an sante akeyi
Laj 18 a 60 · Tout sèks · Mizajou Aug 28, 2026 · NCT05545306

Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

  • Arizona Clinical Trials, Chandler
  • Epic Medical Research - Sun City, Sun City
Ap rekriteFaz 3
Laj 18 a 99 · Tout sèks · Mizajou Aug 27, 2026 · NCT07575399

A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

  • Research Site, Mesa
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 25, 2026 · NCT07784725

Redefining Evaluation of Adiposity and Leanness: Broadening Objective Diagnostics for Obesity

  • Exponent Phoenix, Phoenix
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Aug 20, 2026 · NCT07776678

A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

  • Mercy Gilbert Medical Center, Gilbert
  • Sun City Clinical Research, Glendale
  • Honor Health, Phoenix
  • ak 1 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 18, 2026 · NCT07567001

Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

  • ACCOMPLISH-1 Research Site, Phoenix
  • ACCOMPLISH-1 Research Site, Sun City West
  • ACCOMPLISH-1 Research Site, Tucson
Ap rekriteFaz 3
Laj 18 a 79 · Tout sèks · Mizajou Aug 10, 2026 · NCT07654361

Fibrosis Lessens After Metabolic Surgery

  • Banner Health Center, Phoenix
Ap rekriteFaz 4Volontè an sante akeyi
Laj 18 a 75 · Tout sèks · Mizajou Jul 31, 2026 · NCT06374875

A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

  • Arizona Research Center, Inc., Phoenix
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Jul 9, 2026 · NCT07481630

A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)

  • Arizona Liver Health, Chandler
  • Adobe Clinical Research, Tucson
Ap rekriteFaz 1/2
Laj 18 a 65 · Tout sèks · Mizajou Jul 8, 2026 · NCT06836609

Investigating the Link Between Type 2 Immunity and NAFLD in Human Obesity

  • Mayo Clinic in Arizona, Scottsdale
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 30 a 70 · Tout sèks · Mizajou Jan 28, 2026 · NCT04232566

Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation

  • The University of Arizona College of Medicine- Phoenix, Phoenix
Ap rekriteFaz 3
Laj 18 a 75 · Tout sèks · Mizajou Nov 14, 2025 · NCT06499857

A Culturally-relevant Micronutrient-dense Plant-rich (mNDPR) Dietary Intervention for Native Americans

  • PRANDIAL Lab, Flagstaff
Ap rekriteVolontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Nov 14, 2024 · NCT04755062

Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.